What is the pathophysiology of the neurologic and psychiatric manifestations of Cushing syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Neurologic and Psychiatric Manifestations in Cushing Syndrome

The neurologic and psychiatric symptoms of Cushing syndrome result primarily from excess endogenous glucocorticoids causing structural brain damage, particularly cerebral atrophy with selective vulnerability of the hippocampus and frontal/temporal lobes, leading to cognitive impairment and depression. 1

Primary Pathophysiologic Mechanism

Excess circulating glucocorticoids directly damage brain tissue through multiple mechanisms:

  • Brain atrophy develops in both adults and children with active Cushing syndrome, with considerable cerebral atrophy documented at diagnosis 1
  • Grey matter volume loss occurs diffusely but shows selective persistence in frontal and temporal lobes even after remission, regions strongly associated with cognition and memory 1
  • Hippocampal damage is particularly prominent, with decreased glucose utilization leading to neurogenesis impairment, inhibition of long-term potentiation, and decreased neurotrophic factors 2

Specific Neurobiological Mechanisms

At the cellular level, glucocorticoid excess causes:

  • Hippocampal structural changes including alterations in neurogenesis, neuronal morphology, signaling pathways, and gene expression 2
  • Glutamate accumulation in hippocampal tissue, contributing to excitotoxic damage 2
  • Impaired glucose metabolism in brain tissue, which may explain the mechanisms of glucocorticoid-induced brain atrophy 2
  • Damage to basal ganglia in addition to hippocampal injury 2

Clinical Manifestations by System

Psychiatric Symptoms

Depression is the most common psychiatric manifestation:

  • Major depression occurs most frequently, along with emotional instability, anxiety disorders, and impulsivity 2, 3, 4
  • Mania and psychosis are less common but well-documented complications 5, 4
  • These symptoms are directly associated with excess endogenous circulating glucocorticoids 1

Cognitive Impairments

Multiple cognitive domains are affected:

  • Episodic and working memory deficits are prominent features 5
  • Executive function and attention are impaired at diagnosis 5
  • Paradoxical cognitive decline can occur even after successful surgical cure, despite reversal of brain atrophy 1

Reversibility and Long-Term Consequences

Critical distinction between reversible and irreversible changes:

  • Almost complete reversal of cerebral atrophy occurs within 1 year after transsphenoidal surgery cure 1
  • Grey matter volume loss reverses within 3 months after remission, except in frontal and temporal lobes which remain affected 1
  • Long-term cognitive and memory problems persist in approximately 25% of patients despite successful treatment 1
  • Severe psychiatric and behavioral symptoms show notable improvement after cure, but complete recovery is not universal 1

Important Clinical Pitfalls

The paradoxical post-treatment decline requires awareness:

  • Despite near-complete reversal of structural brain atrophy at 1 year post-surgery, a paradoxical decline in cognitive function can occur 1
  • This dissociation between structural recovery and functional improvement underscores that irreversible effects of previous glucocorticoid excess on the central nervous system may persist 2
  • Long-standing hypercortisolism may cause irreversible pathological damage and induce highly individualized affective responses 4

Monitoring Implications

Given these pathophysiologic mechanisms, the 2024 Nature Reviews Endocrinology consensus guideline recommends:

  • Long-term monitoring for psychiatric and neurocognitive comorbidities following remission of Cushing disease, in addition to lifelong endocrine follow-up 1
  • Health-related quality of life remains impaired and is not fully resolved at 1 year post-treatment 1

Related Questions

What's the next step in evaluating a 37-year-old woman with persistent anxiety, significant unintentional weight loss, paresthesias, and cognitive impairment, after a negative Cushing's (Cushing's syndrome) workup and normal thyroid studies, vitamin B12 levels, and negative screens for pheochromocytoma and celiac disease, who is currently taking fluoxetine (fluoxetine), escitalopram (escitalopram), divalproex (valproate), buspirone (buspirone), and dextroamphetamine-amphetamine (amphetamine and dextroamphetamine)?
What is the appropriate evaluation and treatment approach for a patient presenting with unspecified symptoms and medical history?
What is the cause of anxiety, weight loss, paresthesias, and cognitive impairment in a patient with a history of treatment with fluoxetine, escitalopram, divalproex, buspirone, dextroamphetamine-amphetamine, and Lybalvi, with Cushing's syndrome ruled out?
What are the clinical features of Cushing syndrome?
What is the likely diagnosis and recommended treatment plan for a patient with Cushing's syndrome symptoms, including hot flashes, moon face, skin changes, joint issues, trigeminal neuralgia, facial paralysis, eye irritation, suspected CSF leak, frequent illnesses, and anxiety?
Can hypocalcemia cause seizures in pediatric patients?
In a patient with deep pressure‑like perineal discomfort, reduced sexual sensation, mild bladder irritation after a single prolonged straining event three years ago, intact continence and normal superficial perineal sensation, is this consistent with pudendal neuropathy, pudendal neuralgia, or pelvic‑floor muscle hypertonicity?
In a palliative care patient on mechanical ventilation, how should the ABCDEF bundle (Assess pain, Both spontaneous awakening/breathing trials, Choice of sedation, Delirium management, Early mobility, Family engagement) be applied to prioritize comfort and quality of life?
What are anti‑synthetase antibodies, the associated clinical triad (myositis, interstitial lung disease, mechanic’s hands), diagnostic work‑up, and recommended treatment?
How should uncomplicated cellulitis be treated in a 71‑year‑old woman?
Is niacinamide safe for a patient with Parkinson's disease who is taking levodopa‑carbidopa?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.